{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:44Z","timestamp":1784667704263,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Siglecs (sialic acid-binding immunoglobulin-like lectins) are immune receptors that modulate leukocyte signaling and influence tumor immunosurveillance. Tumor cells exploit Siglec\u2013sialic acid interactions via hypersialylation to dampen anti-tumor immunity. Sentinel lymph nodes (SLNs) can be conditioned by tumors to form immunosuppressive environments supporting metastasis. This study analyzes Siglec receptor expression in SLN- associated T cells from OSCC patients and evaluates correlations with tumor stage (T stage) and nodal metastasis (N stage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sentinel lymph nodes (SLNs) were collected from OSCC patients undergoing SLN mapping\/biopsy as part of standard care. Healthy lymph nodes (HLNs) were collected from non-cancer controls undergoing surgery for benign conditions. Immune cells were isolated and Siglec expression on CD4\u207a and CD8\u207a T cells were quantified using flow cytometry. Within the OSCC cohort, SLNs were classified as metastasis-negative (M\u207b) or metastasis-positive (M\u207a) based on histopathological assessment. Expression levels were compared between lymph node types and correlated with clinical staging parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Distinct patterns of Siglec expression were observed between CD4\u2009+\u2009and CD8\u2009+\u2009T-cell subsets. Siglec-3 expression on SLN T cells was decreased in metastasis-positive (M\u207a) SLNs compared with metastasis-negative (M\u207b) SLNs.s. Similarly, Siglec-5 expression on T cells was decreased in SLNs from patients with higher primary tumor stage (T stage) and more extensive nodal metastasis (N stage).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SLN immune cells exhibit distinctive Siglec expression changes associated with tumor progression. Downregulation of Siglec-3 and Siglec-5 on T cells in metastatic or advanced-stage disease, suggests that Siglec-mediated immune regulation contributes to the immunosuppressive pre-metastatic niche. These findings provide first-time evidence of altered Siglec pathways in SLNs, highlighting their potential utility as immune biomarkers and therapeutic targets in solid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00405-026-10276-y","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:07:14Z","timestamp":1779332834000},"page":"4715-4723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Siglec expression in sentinel lymph nodes in patients with oral squamous cell carcinoma"],"prefix":"10.1007","volume":"283","author":[{"given":"Lars Olaf","family":"Cardell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo I.","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Piersiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-9255","authenticated-orcid":false,"given":"Susanna","family":"Kumlien Geor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"10276_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC (2020) Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol 38:365\u2013395","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10276_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nri3737","volume":"14","author":"MS Macauley","year":"2014","unstructured":"Macauley MS, Crocker PR, Paulson JC (2014) Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 14(10):653\u2013666","journal-title":"Nat Rev Immunol"},{"key":"10276_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cbpa.2021.01.001","volume":"62","author":"G Murugesan","year":"2021","unstructured":"Murugesan G, Weigle B, Crocker PR (2021) Siglec and anti-Siglec therapies. Curr Opin Chem Biol 62:34\u201342","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"10276_CR4","first-page":"238","volume":"1846","author":"C B\u00fcll","year":"2014","unstructured":"B\u00fcll C, den Brok MH, Adema GJ (2014) Sweet escape: sialic acids in tumor immune evasion. Biochim Biophys Acta 1846(1):238\u2013246","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10276_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14728222.2019.1667977","volume":"23","author":"A B\u00e4renwaldt","year":"2019","unstructured":"B\u00e4renwaldt A, L\u00e4ubli H (2019) The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity. Expert Opin Ther Targets 23(10):839\u2013853","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10276_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1189\/jlb.0205096","volume":"79","author":"T Hern\u00e1ndez-Caselles","year":"2006","unstructured":"Hern\u00e1ndez-Caselles T, Mart\u00ednez-Esparza M, P\u00e9rez-Oliva AB, Quintanilla-Cecconi AM, Garc\u00eda-Alonso A, Alvarez-L\u00f3pez DM et al (2006) A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 79(1):46\u201358","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10276_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/imm.13470","volume":"166","author":"A Vuchkovska","year":"2022","unstructured":"Vuchkovska A, Glanville DG, Scurti GM, Nishimura MI, White P, Ulijasz AT et al (2022) Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. Immunology 166(2):238\u2013248","journal-title":"Immunology"},{"issue":"2","key":"10276_CR8","doi-asserted-by":"publisher","first-page":"e0229089","DOI":"10.1371\/journal.pone.0229089","volume":"15","author":"X Pang","year":"2020","unstructured":"Pang X, Fan HY, Tang YL, Wang SS, Cao MX, Wang HF et al (2020) Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS ONE 15(2):e0229089","journal-title":"PLoS ONE"},{"key":"10276_CR9","doi-asserted-by":"publisher","first-page":"790317","DOI":"10.3389\/fimmu.2021.790317","volume":"12","author":"EJH van Houtum","year":"2021","unstructured":"van Houtum EJH, B\u00fcll C, Cornelissen LAM, Adema GJ (2021) Siglec Signaling in the Tumor Microenvironment. Front Immunol 12:790317","journal-title":"Front Immunol"},{"issue":"1","key":"10276_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/hed.27207","volume":"45","author":"SS Jang","year":"2023","unstructured":"Jang SS, Davis ME, Vera DR, Lai SY, Guo TW (2023) Role of sentinel lymph node biopsy for oral squamous cell carcinoma: Current evidence and future challenges. Head Neck 45(1):251\u2013265","journal-title":"Head Neck"},{"key":"10276_CR11","first-page":"8e48916","volume":"24","author":"R Singh","year":"2019","unstructured":"Singh R, Choi BK (2019) Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis. Elife Dec 24:8e48916","journal-title":"Elife Dec"},{"issue":"1","key":"10276_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1245\/aso.2002.9.1.82","volume":"9","author":"SP Leong","year":"2002","unstructured":"Leong SP, Peng M, Zhou YM, Vaquerano JE, Chang JW (2002) Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 9(1):82\u201387","journal-title":"Ann Surg Oncol"},{"key":"10276_CR13","doi-asserted-by":"publisher","first-page":"691937","DOI":"10.3389\/fcell.2021.691937","volume":"9","author":"H Du","year":"2021","unstructured":"Du H, Tang J, Li X, Wang X, Wu L, Zhang R et al (2021) Siglec-15 Is an Immune Suppressor and Potential Target for Immunotherapy in the Pre-Metastatic Lymph Node of Colorectal Cancer. Front Cell Dev Biol 9:691937","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"10276_CR14","doi-asserted-by":"publisher","first-page":"12524","DOI":"10.1002\/cam4.5966","volume":"12","author":"R Bark","year":"2023","unstructured":"Bark R, Kolev A, Elliot A, Piersiala K, N\u00e4sman A, Gryb\u00e4ck P et al (2023) Sentinel node-assisted neck dissection in advanced oral squamous cell carcinoma-A new protocol for staging and treatment. Cancer Med 12(11):12524\u201312534","journal-title":"Cancer Med"},{"issue":"31","key":"10276_CR15","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.2174\/1381612826666200213100750","volume":"26","author":"\u00c5 K\u00e5gedal","year":"2020","unstructured":"K\u00e5gedal \u00c5, Margolin G, Held C, da Silva PFN, Piersiala K, Munck-Wikland E et al (2020) A Novel Sentinel Lymph Node Approach in Oral Squamous Cell Carcinoma. Curr Pharm Des 26(31):3834\u20133839","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10276_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-18-0505","volume":"7","author":"Q Haas","year":"2019","unstructured":"Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA et al (2019) Siglec-9 Regulates an Effector Memory CD8(+) T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunol Res 7(5):707\u2013718","journal-title":"Cancer Immunol Res"},{"key":"10276_CR17","doi-asserted-by":"publisher","first-page":"996746","DOI":"10.3389\/fimmu.2022.996746","volume":"13","author":"Q Haas","year":"2022","unstructured":"Haas Q, Markov N, Muerner L, Rubino V, Benjak A, Haubitz M et al (2022) Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8\u2009+\u2009T cells with high functional and metabolic capacities. Front Immunol 13:996746","journal-title":"Front Immunol"},{"issue":"11","key":"10276_CR18","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1172\/JCI120612","volume":"128","author":"MA Stanczak","year":"2018","unstructured":"Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S et al (2018) Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest 128(11):4912\u20134923","journal-title":"J Clin Invest"},{"issue":"9","key":"10276_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nri1919","volume":"6","author":"AJ Cochran","year":"2006","unstructured":"Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6(9):659\u2013670","journal-title":"Nat Rev Immunol"},{"key":"10276_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers13153896","volume":"13","author":"K Montalb\u00e1n-Hern\u00e1ndez","year":"2021","unstructured":"Montalb\u00e1n-Hern\u00e1ndez K, Cantero-Cid R, Lozano-Rodr\u00edguez R, Pascual-Iglesias A, Avenda\u00f1o-Ortiz J, Casalvilla-Due\u00f1as JC et al (2021) Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients. Cancers (Basel) 13:15","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10276_CR21","doi-asserted-by":"publisher","first-page":"17141","DOI":"10.3390\/ijms242417141","volume":"24","author":"C Van BoutiP, Blans","year":"2023","unstructured":"BoutiP, Blans C, Klein B, Shome D, Nadafi R, Van Houdt M et al (2023) SIGLEC-5\/14 inhibits CD11b\/CD18 integrin activation and neutrophil-mediated tumor cell cytotoxicity. Int J Mol Sci 24(24):17141 https:\/\/doi.org\/10.3390\/ijms242417141","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10276_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","volume":"77","author":"H L\u00e4ubli","year":"2020","unstructured":"L\u00e4ubli H, Varki A (2020) Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell Mol Life Sci 77(4):593\u2013605","journal-title":"Cell Mol Life Sci"},{"key":"10276_CR23","first-page":"1","volume":"75","author":"R Schauer","year":"2018","unstructured":"Schauer R, Kamerling JP (2018) Exploration of the Sialic Acid World. Adv Carbohydr Chem Biochem 75:1\u2013213","journal-title":"Adv Carbohydr Chem Biochem"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10276-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:06:26Z","timestamp":1784664386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10276-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10276"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10276-y","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None to declare.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}